South Korea caps liraglutide prescribing to 6 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 10 of 25 of this archive, newest first.
Efficacy was never the question in this appraisal. Duration of treatment was.
Efficacy was never the question in this appraisal. Duration of treatment was.
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
A withdrawal trial answers a narrower question than it appears to. This piece states which question.
Efficacy was never the question in this appraisal. Duration of treatment was.
Reported from the sessions, and from the two hours afterwards.
Efficacy was never the question in this appraisal. Duration of treatment was.
Efficacy was never the question in this appraisal. Duration of treatment was.
Reported from the sessions, and from the two hours afterwards.
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
Reported from the sessions, and from the two hours afterwards.
Reported from the sessions, and from the two hours afterwards.
Reported from the sessions, and from the two hours afterwards.
Efficacy was never the question in this appraisal. Duration of treatment was.
Reported from the sessions, and from the two hours afterwards.
Reported from the sessions, and from the two hours afterwards.
Reported from the sessions, and from the two hours afterwards.
Reported from the sessions, and from the two hours afterwards.
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
Efficacy was never the question in this appraisal. Duration of treatment was.